Prescription Medicines
Hebicom Cap.
- Product Category
- Liver disease medication
- Active Ingredients
- Biphenyldimethyldicarboxylate, ursodeoxycholic acid
- Appearance
- A hard capsule with a white cap and body, containing white powder.
- Reimbursement Code
- 648104020
01 / 02
1. Composition and Strength
Of 1 capsule
- Active ingredient: Biphenyldimethyldicarboxylate (in-house specification)----12.5mg
Ursodeoxycholic acid (KP)------------------------50mg
- Additives (animal-derived ingredients): lactose hydrate (cow, milk), gelatin (cow, leather)
- Other additives: magnesium stearate, corn starch, capsule, polysorbate 80, polyethylene glycol 8000
2. Effectiveness
Chronic persistent hepatitis with continuously elevated SGPT
3. Dosage and dosage
Usually, adults take 1 capsule at a time, orally, 3 times a day after meals.
4. Precautions for use
1. Do not administer to the following patients
1) Patients with complete biliary obstruction
2) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
2. Administer with caution to the following patients:
1) Patients with chronic active hepatitis
2) Patients with cirrhosis
3) Patients with hypokalemia
4) Patients with severe pancreatic disease
5) Patients with peptic ulcer
6) Patients with cholelithiasis
3. Side effects
1) Digestive system: Occasionally, symptoms such as diarrhea, nausea, vomiting, and rarely abdominal pain, constipation, heartburn, and stomach discomfort may appear.
2) Hypersensitivity: Occasionally hypersensitivity symptoms such as itching and rarely rash may occur. Occasionally, rash may occur, but it usually disappears with the concurrent use of anti-hypersensitivity medication.
3) Transient jaundice may appear, but it disappears when the medication is stopped or jaundice treatment is administered concurrently.
4) Others: In rare cases, general malaise and dizziness may occur.
5) Domestic post-marketing survey results
As a result of a post-marketing use outcome study conducted on 640 patients with chronic persistent hepatitis over 6 years for re-examination in Korea, the rate of adverse events and adverse drug reactions was reported to be 0.31% (2 people/640 people, 3 cases), and cirrhosis, ascites, and acute hepatitis C were each reported to be 0.16% (1 person/640 people, 1 case). These were all serious and unexpected adverse drug reactions, and a causal relationship with this drug could not be ruled out.
4. General precautions
1) Stick to the prescribed dosage.
2) If symptoms do not improve despite long-term use (up to 8 weeks), or if abnormal symptoms appear due to taking this drug, stop taking the drug and consult a doctor or pharmacist.
3) Keep out of reach of children.
5. Administration to pregnant women
Since fetal toxicity has been reported in animal experiments, it is advisable not to administer to pregnant women or women who may be pregnant.
6. Interaction
When administered in combination with oral diabetes drugs (tolbutamide, etc.), the effect of oral diabetes drugs may be increased, so administer with caution.
7. Pharmaceutical equivalence test information
The test drug Biphenyldimethyldicarboxylate/ursodeoxycholic acid capsule 12.5/50 mg (Nexpharm Korea Co., Ltd.) and the control drug UDB capsule (Pharmarking Co., Ltd.) were administered orally once on an empty stomach to healthy adults in a 2 When comparative evaluation item values (AUCt, Cmax) were log-transformed and subjected to statistical processing, the 90% confidence interval of the mean difference was within log 0.8 to log 1.25, proving biological equivalence.
※Refer to table attached document
Note 1. This drug was manufactured by Nexpharm Korea Co., Ltd. with the entire process using the same raw materials as Nexpharm Korea's Biphenyldimethyldicarboxylate/ursodeoxycholic acid capsule 12.5/50 mg using the same manufacturing method.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 capsules/bottle, 300 capsules/bottle
7. Period of use
36 months from date of manufacture
Of 1 capsule
- Active ingredient: Biphenyldimethyldicarboxylate (in-house specification)----12.5mg
Ursodeoxycholic acid (KP)------------------------50mg
- Additives (animal-derived ingredients): lactose hydrate (cow, milk), gelatin (cow, leather)
- Other additives: magnesium stearate, corn starch, capsule, polysorbate 80, polyethylene glycol 8000
2. Effectiveness
Chronic persistent hepatitis with continuously elevated SGPT
3. Dosage and dosage
Usually, adults take 1 capsule at a time, orally, 3 times a day after meals.
4. Precautions for use
1. Do not administer to the following patients
1) Patients with complete biliary obstruction
2) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
2. Administer with caution to the following patients:
1) Patients with chronic active hepatitis
2) Patients with cirrhosis
3) Patients with hypokalemia
4) Patients with severe pancreatic disease
5) Patients with peptic ulcer
6) Patients with cholelithiasis
3. Side effects
1) Digestive system: Occasionally, symptoms such as diarrhea, nausea, vomiting, and rarely abdominal pain, constipation, heartburn, and stomach discomfort may appear.
2) Hypersensitivity: Occasionally hypersensitivity symptoms such as itching and rarely rash may occur. Occasionally, rash may occur, but it usually disappears with the concurrent use of anti-hypersensitivity medication.
3) Transient jaundice may appear, but it disappears when the medication is stopped or jaundice treatment is administered concurrently.
4) Others: In rare cases, general malaise and dizziness may occur.
5) Domestic post-marketing survey results
As a result of a post-marketing use outcome study conducted on 640 patients with chronic persistent hepatitis over 6 years for re-examination in Korea, the rate of adverse events and adverse drug reactions was reported to be 0.31% (2 people/640 people, 3 cases), and cirrhosis, ascites, and acute hepatitis C were each reported to be 0.16% (1 person/640 people, 1 case). These were all serious and unexpected adverse drug reactions, and a causal relationship with this drug could not be ruled out.
4. General precautions
1) Stick to the prescribed dosage.
2) If symptoms do not improve despite long-term use (up to 8 weeks), or if abnormal symptoms appear due to taking this drug, stop taking the drug and consult a doctor or pharmacist.
3) Keep out of reach of children.
5. Administration to pregnant women
Since fetal toxicity has been reported in animal experiments, it is advisable not to administer to pregnant women or women who may be pregnant.
6. Interaction
When administered in combination with oral diabetes drugs (tolbutamide, etc.), the effect of oral diabetes drugs may be increased, so administer with caution.
7. Pharmaceutical equivalence test information
The test drug Biphenyldimethyldicarboxylate/ursodeoxycholic acid capsule 12.5/50 mg (Nexpharm Korea Co., Ltd.) and the control drug UDB capsule (Pharmarking Co., Ltd.) were administered orally once on an empty stomach to healthy adults in a 2 When comparative evaluation item values (AUCt, Cmax) were log-transformed and subjected to statistical processing, the 90% confidence interval of the mean difference was within log 0.8 to log 1.25, proving biological equivalence.
※Refer to table attached document
Note 1. This drug was manufactured by Nexpharm Korea Co., Ltd. with the entire process using the same raw materials as Nexpharm Korea's Biphenyldimethyldicarboxylate/ursodeoxycholic acid capsule 12.5/50 mg using the same manufacturing method.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 capsules/bottle, 300 capsules/bottle
7. Period of use
36 months from date of manufacture